Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 276 to 300 of 374

Guidance and quality standards awaiting development
Title	Type
Secukinumab for treating relapsed polymyalgia rheumatica [ID6599]	Technology appraisal guidance
Selinexor with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 to 4 treatment lines in people who have not had pomalidomide [ID6705]	Technology appraisal guidance
Selinexor with ruxolitinib for treating splenomegaly or symptoms in myelofibrosis untreated with a JAK inhibitor [ID6717]	Technology appraisal guidance
Semaglutide 7.2 mg single-dose device for managing overweight and obesity [ID6699]	Technology appraisal guidance
Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]	Technology appraisal guidance
Semaglutide for treating type 2 diabetes [ID1450]	Technology appraisal guidance
Sepiapterin for treating hyperphenylalaninaemia in phenylketonuria in people of any age [ID6750]	Technology appraisal guidance
Serplulimab with chemotherapy for neoadjuvant and adjuvant treatment of untreated gastric cancer [TSID12350]	Technology appraisal guidance
Setrusumab for treating osteogenesis imperfecta [ID6730]	Technology appraisal guidance
Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]	Technology appraisal guidance
Shared decision-making: practical guidance for health and social care professionals	Quality standard
Sibeprenlimab for treating IgA nephropathy [ID6604]	Technology appraisal guidance
Sigvotatug vedotin for Non-small-cell lung cancer [ID6718]	Technology appraisal guidance
Sleep disordered breathing	Quality standard
Social work interventions for adults with complex needs (including learning disabilities) and mental health needs	Quality standard
Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536]	Technology appraisal guidance
Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621]	Technology appraisal guidance
Sonesitatug vedotin for previously treated metastatic claudin 18.2-positive gastric or gastro-oesophageal junction adenocarcinomar [ID6669]	Technology appraisal guidance
Sotagliflozin for treating type 2 diabetes [ID1657]	Technology appraisal guidance
Sotorasib with pemetrexed and carboplatin for untreated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6741]	Technology appraisal guidance
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]	Technology appraisal guidance
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]	Technology appraisal guidance
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]	Technology appraisal guidance
Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081	Technology appraisal guidance
Sugemalimab for consolidation treatment of locally advanced or unresectable non-small-cell lung cancer after chemoradiotherapy [ID6737]	Technology appraisal guidance

Results per page

10
25
50
All